NCT04666662 (PREDICTR) is a clinical trial in Depression, sponsored by University of York.

Who is sponsoring NCT04666662?

NCT04666662 is sponsored by University of York.

What condition does NCT04666662 study?

NCT04666662 studies Depression.

Is NCT04666662 still recruiting?

NCT04666662 is currently completed. Last updated 25 June 2024.

Last reviewed 2024-06-25 · How we verify

NCT04666662: PREDICTR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prognostic Model to PREDICT Relapse of Depression in Primary Care

Completed Last updated 25 June 2024

What this trial tests

trial in Depression in 1,244 participants. Completed in 24 June 2024.

Timeline

1 February 2021

Primary endpoint
24 June 2024

24 June 2024

Quick facts

Lead sponsor	University of York
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,244
Start date	1 February 2021
Primary completion	24 June 2024
Estimated completion	24 June 2024
Sites	1 location across United Kingdom

Conditions studied

Depression — all drugs for Depression →

Sponsor

University of York

Who can join

18 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to develop a prognostic model to predict the risk of relapse within 6-8 months of patients entering remission. The long-term objective is to facilitate more efficient targeting of evidence-based relapse prevention strategies to these patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The development and validation of a prognostic model to PREDICT Relapse of depression in adult patients in primary care: protocol for the PREDICTR study.
Moriarty AS, Paton LW, Snell KIE, Riley RD, et al · · 2021 · cited 6× · PMID 34215317 · DOI 10.1186/s41512-021-00101-x
Development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies.
Moriarty AS, Paton LW, Snell KIE, Archer L, et al · · 2024 · cited 1× · PMID 39467616 · DOI 10.1136/bmjment-2024-301226
The development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies
Moriarty AS, Paton LW, Snell KI, Archer L, et al · · 2024 · DOI 10.1101/2024.06.25.24309402

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other University of York trials

Trials by the same sponsor.

NCT04342715 — A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis · active not recruiting
NCT04104555 — Orthotics for Treatment of Symptomatic Flat Feet in Children · NA · completed
NCT04512742 — A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies · NA · completed
NCT04291547 — Computerised Behavioural Activation for Young People With Depression · NA · completed
NCT03969134 — A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04666662 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of York
Last refreshed: 25 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04666662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing